Pioglitazone and metformin

Drugs of Today

Volumn 43, Issue 7, 2007, Pages 443-454

  Hill, Nathan R ^a   Matthews, David R ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; COMPETACT; GEMFIBROZIL; GLICLAZIDE; GLIMEPIRIDE PLUS PIOGLITAZONE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS ROSIGLITAZONE; NONSTEROID ANTIINFLAMMATORY AGENT; PIOGLITAZONE; PROINSULIN; RIFAMPICIN; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADD ON THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EPIGASTRIC DISCOMFORT; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; REVIEW; TASTE DISORDER;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; THERAPEUTIC EQUIVALENCY; THIAZOLIDINEDIONES;

EID: 34548316762     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.7.1119722     Document Type: Review

References (48)

1. Elbrecht, A., Chen, Y., Cullinan, C.A. et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun 1996, 224: 431-7.
2. Spiegelman, B.M. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47: 507-14.
3. Tan, M.H. Current treatment of insulin resistance in type 2 diabetes mellitus. Int J Clin Pract Suppl 2000, 113: 54-62.
4. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetol 1985, 28: 412-9.
5. Wallace, T.M., Levy, J.C., Matthews, D.R. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004, 21: 568-76.
6. Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J.W., Mathisen, A.L., Schneider, R.L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000, 23: 1605-11.
7. Miyazaki, Y., Mahankali, A., Matsuda, M. et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001, 24: 710-9.
8. Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., Gerich, J.E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995, 333: 550-4.
9. Natali, A., Ferrannini, E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: A systematic review. Diabetol 2006, 49: 434-41.
10. Cheng, J.T., Huang, C.C., Liu, I.M., Tzeng, T.F., Chang, C.J. Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats. Diabetes 2006, 55: 819-25.
11. Huypens, P., Quartier, E., Pipeleers, D., Van de Casteele, M. Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase. Eur J Pharmacol 2005, 518: 90-5.
12. Richardson, H., Campbell, S.C., Smith, S.A., Macfarlane, W.M. Effects of rosiglitazone and metformin on pancreatic beta cell gene expression. Diabetol 2006, 49: 685-96.
13. EMEA. Pioglitazone and metformin combination. Available at: http://www.emea.eu.int. Cited 2006.
14. Einhorn, D., Rendell, M., Rosenzweig, J., Egan, J.W., Mathisen, A.L., Schneider, R.L. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000, 22: 1395-409.
15. Rendell, M.S., Glazer, N.B., Ye, Z. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with type 2 diabetes: Influence of prior antidiabetic drug regimen. J Diabetes Complications 2003, 17: 211-7.
16. Matthews, D.R., Charbonnel, B.H., Hanefeld, M., Brunetti, P., Schernthaner, G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: A randomized, comparative study. Diabetes/Metabolism Research Reviews 2005, 21: 167-74.
17. Derosa, G., D'Angelo, A., Ragonesi, P.D. et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006, 31: 375-83.
18. Perez, A., Khan, M., Johnson, T., Karunaratne, M. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diab Vasc Dis Res 2004, 1: 44-50.
19. Charbonnel, B., Schernthaner, G., Brunetti, P. et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetol 2005, May 12.
20. Belcher, G., Lambert, C., Edwards, G., Urquhart, R., Matthews, D.R. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2005, 70: 53-62.
21. Sato, M., Yajima, Y., Kawashima, S., Tanaka, K., Kagechika, H. Synergistic potentiation of thiazolidinedione-induced ST 13 preadipocyte differentiation by RAR synergists. Biochem Biophys Res Commun 2001, 280: 646-51.
22. Betteridge, D.J., Verges, B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetol 2005, 48: 2477-81.
23. Gerstein, H.C., Yusuf, S., Holman, R., Bosch, J., Pogue, J. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: The DREAM trial. Diabetol 2004, 47: 1519-27.
24. Viberti, G., Kahn, S.E., Greene, D.A. et al. A diabetes outcome progression trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002, 25: 1737-43.
25. Kipnes, M.S., Krosnick, A., Rendell, M.S. et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study. Am J Med 2001, 111: 10-7.
26. Derosa, G., Cicero, A.F., Gaddi, A. et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005, 69: 5-13.
27. Compectant® prescribing information. Takeda Pharmaceutical Company Ltd. 2007. Available at: http://www.takeda.co.uk/product_information/ CompetactPIJan2007.pdf.
28. Electronic Medicines Compendium, 2007. Available at: http://emc. medicines.org.uk. Cited Feb 27, 2007.
29. Song, S. The role of increased liver triglyceride content: A culprit of diabetic hyperglycaemia? Diabetes Metab Res Rev 2002, 18: 5-12.
30. Miyazaki, Y., Mahankali, A., Matsuda, M. et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002, 87: 2784-91.
31. Bajaj, M., Suraamornkul, S., Pratipanawatr, T. et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003, 52: 1364-70.
32. EMEA European Public Assessment Report (EPAR) - Competact, 2006 (cited Feb. 17, 2007). Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ competact/H-655-en1.pdf.
33. Ceriello, A., Johns, D., Widel, M., Eckland, D.J., Gilmore, K.J., Tan, M.H. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005, 28: 266-72.
34. Jaakkola, T., Backman, J.T., Neuvonen, M., Neuvonen, P.J. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 2005, 77: 404-14.
35. Deng, L.J., Wang, F., Li, H.D. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 2005, 61: 831-6.
36. Jaakkola, T., Backman, J.T., Neuvonen, M., Laitila, J., Neuvonen, P. J. Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol 2006, 61: 70-8.
37. Rajagopalan, R., Xu, Y., Abbadessa, M. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: A post hoc analysis of four randomized trials. Am J Geriatr Pharmacother 2006, 4: 123-33.
38. Charbonnel, B.H., Matthews, D.R., Schernthaner, G., Hanefeld, M., Brunetti, P. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: A randomized, double-blind, parallel-group comparison trial. Diabet Med 2005, 22: 399-405.
39. Schernthaner, G., Matthews, D.R., Charbonnel, B., Hanefeld, M., Brunetti, P. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: A double-blind, randomized trial. J Clin Endocrinol Metab 2004, 89: 6068-76.
40. Monnier, L., Sauvanet, J.P. Pioglitazone insulin sensitivity and type 2 diabetes mellitus: Recent data. Ann Endocrinol (Paris) 2004, 65: 136-48.
41. Hanefeld, M., Brunetti, P., Schernthaner, G.H., Matthews, D.R., Charbonnel, B.H. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004, 27: 141-7.
42. Wallace, T.M., Levy, J.C., Matthews, D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27: 1487-95.
43. Nathan, D.M., Buse, J.B., Davidson, M.B. et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006, 29: 1963-72.
44. Argaud, D., Roth, H., Wiernsperger, N., Leverve, X.M. Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes. Eur J Biochem 1993, 213: 1341-8.
45. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352: 854-65.
46. Matthews, D.R., Cull, C.A., Stratton, I.M., Holman, R.R., Turner, R.C. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998, 15: 297-303.
47. Wallace, T.M., Matthews, D.R. Coefficient of failure: A methodology for examining longitudinal beta-cell function in type 2 diabetes. Diabet Med 2002, 19: 465-9.
48. Dormandy, J.A., Charbonnel, B., Eckland, D.J. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): A randomised controlled trial. Lancet 2005, 366: 1279-89.